ETON Company Profile and Key Details

Q: Who are the executives of ETON?

Mr. Scott GrossenbachVice President of Sales & MarketingMr. Kevin GuthrieExecutive Vice President of Commercial OperationsMr. Sean E. BrynjelsenPres, Chief Executive Officer & DirectorMr. James R. Gruber CPAChief Financial Officer, Treasurer & Sec.Mr. David C. KrempaChief Bus. OfficerMs. Ingrid HoosSenior Vice President of Regulatory AffairsMr. David KrempaChief Bus. Officer

NASDAQ : ETON

Eton Pharmaceuticals

$18.92

-0.09-0.47%

At Close 4:00 PM

69.67

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Eton Pharmaceuticals, Inc. (ETON) stock declined over -0.47%, trading at $18.92 on NASDAQ, down from the previous close of $19.01. The stock opened at $19.21, fluctuating between $18.82 and $19.35 in the recent session.

Stock Snapshot

19.01

Prev. Close

507.39M

Market Cap

18.82

Day Low

-72.77

P/E Ratio

-0.26

EPS (TTM)

0.36

Cash Flow per Share

19.21

Open

26.82M

Number of Shares

19.35

Day High

78.38%

Free Float in %

0.66

Book Value

223.19K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 17, 2026	19.01	19.35	18.62	18.92	230.4K
Mar 16, 2026	18.94	19.87	18.78	19.01	333.03K
Mar 13, 2026	19.08	19.19	18.50	18.93	258.11K
Mar 12, 2026	17.74	19.23	17.74	19.02	361.32K
Mar 11, 2026	17.37	18.19	17.00	18.09	311.62K
Mar 10, 2026	16.69	17.65	16.69	17.40	181.43K
Mar 09, 2026	16.61	17.10	16.14	16.70	263.75K
Mar 06, 2026	16.92	17.25	16.62	16.80	228.77K
Mar 03, 2026	17.73	18.08	17.10	17.45	299.36K
Mar 02, 2026	17.05	18.47	16.84	18.15	284.82K
Feb 27, 2026	16.93	17.36	16.80	16.99	234.23K
Feb 26, 2026	17.45	17.53	16.68	17.25	322.91K
Feb 25, 2026	18.26	19.98	16.60	17.65	1.12M
Feb 24, 2026	18.34	18.72	18.04	18.28	426.84K
Feb 23, 2026	17.97	18.53	17.72	18.28	289.75K
Feb 20, 2026	18.16	18.42	17.73	17.93	255.24K
Feb 19, 2026	17.26	18.37	17.18	18.22	254.94K
Feb 18, 2026	17.08	17.56	17.08	17.21	134.34K
Feb 17, 2026	17.27	17.51	16.79	17.15	221.95K
Feb 13, 2026	16.84	17.63	16.79	17.07	326.86K

Contact Details

Deer Park, IL 60010-7208

United States

https://www.etonpharma.com 847 787 7361

About Company

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Stock Peers

REGN

2.14+0.28%

Regeneron Pharmaceuticals, Inc.$759.05 ARGX

2.73+0.39%

argenx SE$706.03 UTHR

5.72001+1.07%

United Therapeutics Corporation$540.02 VRTX

-3.61-0.77%

Vertex Pharmaceuticals Incorporated$462.49 MDGL

2.35+0.53%

Madrigal Pharmaceuticals, Inc.$443.18 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.51+0.47%

Alnylam Pharmaceuticals, Inc.$320.42 PRAX

-1.62-0.53%

Praxis Precision Medicines, Inc.$303.38 KRYS

6.17+2.47%

Krystal Biotech, Inc.$256.33 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) closed at $18.92 USD, losing -$0.09 (-0.47%) from the previous close of $19.01. The stock is currently mid-range between its 52-week high and low $11.09 and $23.00. With a market capitalization of about $507.39 million, Eton Pharmaceuticals, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.24). Key stats such as the average daily volume over the past year has been around 256.46 thousand shares, in line with its 52-week average. Headquartered in Deer Park, IL, Eton Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sean E. Brynjelsen, the company employs approximately 31 people and listed since November 13, 2018. Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases.

Technical Performance

ETON has shown mixed momentum, losing -0.71% over the past week and -15.51% over the past quarter, though year-to-date performance is down -9.17%. Short-term trend indicators are mixed aligned (SMA20 5.64%, SMA50 7.1%, SMA200 2.55%). The stock’s 14-day RSI is 57.36 (neutral), while the ATR of 0.93 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.0% below its high and over 55.59% above its low. Average 10-day trading volume of 277.09 thousand shares is slightly above the 3-month average of 249.22 thousand, indicating heightened recent market interest.

Valuation Metrics

Eton Pharmaceuticals, Inc. trades at a P/E ratio of -76.69, slightly below the S&P 500 average, with a price-to-sales ratio of 7.27 and a price-to-book ratio of 22.16 reflecting a rich premium to book value. The P/FCF stands at 24.32, also above market averages. Compared to sector medians, Eton Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Eton Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$15.06. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Eton Pharmaceuticals, Inc. generated EPS of -$0.25 over the past year. Five-year average earnings growth is 32.22%. The latest quarter delivered EPS of $0.04. The next quarter is forecast at $0.13. Next year's EPS is expected at $2.50 thousand. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $37.00 to $24.00. The high target offers 95.56% upside. The low target suggests 26.85% downside. The mean target is $29.67. This offers 56.82% upside. Eton Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -75.0%. The prior quarter beat by 900.0%. Over the last six quarters, Apple has recorded several small beats. These include 71.43% in August 08, 2024.

Shareholding & Insider Activity

Eton Pharmaceuticals, Inc. has 26.82 million shares outstanding. The public float is 17.96 million shares, elevated short interest at 13.01% of float. This equals 3.32 million shares. The short ratio is 7.46 days. Institutional investors hold 65.35% of the float. Insiders own 4.39%. BRYNJELSEN SEAN holds 2.87 million shares, HARROW HEALTH, INC. has 1.98 million shares and Krempa David has 612.65 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Eton Pharmaceuticals generated $21.25M in revenue, or $0.85 per share. Gross margin was 67.38%, operating margin -38.87%, and net profit margin -46.03%. Returns are negative, with ROA at -39.08% and ROE at -74.80%.
On valuation metrics, Eton Pharmaceuticals trades at a P/E of -76.69, P/S of 7.27 and P/B of 22.16. The current ratio is 1.63 and quick ratio is 1.25. Operationally, the company’s inventory turnover is 2.03 and cash conversion cycle is 95.61 days. Debt-to-equity is 0.14, supported by a cash flow-to-debt ratio of 6.54.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2022, Eton Pharmaceuticals posted revenue of $21.25M, down slightly from $21.83M in the prior quarter. Gross profit was $14.32M (margin 67.38%). Operating income was - $8.26M (margin -38.9%). Net income was- $9.78M (EPS - $0.39).
The company ended the quarter with $16.31M in cash and short-term investments, a total debt of $6.52M, and net debt of - $9.78M. Total assets were $25.03M, with equity of $13.08M. Financials further reflected stability, with operating cash flow of $4.82M, free cash flow of $2.03M, and capital expenditures of - $2.79M.

Price Forecast & Outlook

Our AI price prediction model suggests that Eton Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.61%, with price expected at $20.17 by March 31, 2026, within a range of $19.24 to $21.07 3-Month Outlook: Projected fall of -5.18%, reaching $17.94 by June 15, 2026, with a range of $17.65 to $18.27. 1-Year Outlook: Projected gain of 25.05%, with price at $23.66 by March 17, 2027, within a range of $22.60 to $24.63.

Key Takeaways

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) shares are flat -9.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Eton Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -76.69. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $18.30, suggesting -3.28% downside. Our AI forecast model points to short-term strength (6.61% over two weeks), a medium-term fall (-5.18% over three months), and a longer-term gain (25.05% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Eton Pharmaceuticals, Inc. (ETON) stock price?

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) stock price is $18.92 in the last trading session. During the trading session, ETON stock reached the peak price of $19.35 while $18.82 was the lowest point it dropped to. The percentage change in ETON stock occurred in the recent session was -0.47% while the dollar amount for the price change in ETON stock was - $0.09.

ETON's industry and sector of operation?

The NASDAQ listed ETON is part of Biotechnology industry that operates in the broader Healthcare sector. Eton Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ETON?

Mr. Scott Grossenbach
Vice President of Sales & Marketing
Mr. Kevin Guthrie
Executive Vice President of Commercial Operations
Mr. Sean E. Brynjelsen
Pres, Chief Executive Officer & Director
Mr. James R. Gruber CPA
Chief Financial Officer, Treasurer & Sec.
Mr. David C. Krempa
Chief Bus. Officer
Ms. Ingrid Hoos
Senior Vice President of Regulatory Affairs
Mr. David Krempa
Chief Bus. Officer

How ETON did perform over past 52-week?

ETON's closing price is 70.6% higher than its 52-week low of $11.09 where as its distance from 52-week high of $23.00 is -17.74%.

How many employees does ETON have?

Number of ETON employees currently stands at 31.

Link for ETON official website?

Official Website of ETON is: https://www.etonpharma.com

How do I contact ETON?

ETON could be contacted at phone 847 787 7361 and can also be accessed through its website. ETON operates from 21925 West Field Parkway, Deer Park, IL 60010-7208, United States.

How many shares of ETON are traded daily?

ETON stock volume for the day was 223.19K shares. The average number of ETON shares traded daily for last 3 months was 256.46K.

What is the market cap of ETON currently?

The market value of ETON currently stands at $507.39M with its latest stock price at $18.92 and 26.82M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	31
Beta	1.24
Sales or Revenue	$21.25M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ETON Company Profile and Key Details

Eton Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook